| Field | Detail | Source |
|---|---|---|
| Legal name | iQ3Corp Ltd (Administrators Appointed) | Federal Court of Australia, [2022] FCA 397 (6 Apr 2022) |
| Former names | None recorded | Market Index IQ3 profile |
| ACN | 160 238 282 | FY2020 Annual Report cover; [2022] FCA 397 |
| Incorporation year | 2012 | MarketBeat / Investing.com company profiles (aggregator); consistent with ACN series |
| Incorporation jurisdiction | Australia (public company limited by shares, Corporations Act 2001 (Cth)) | FY2020 AR, Note 1 |
| Registered office / HQ (last reported) | Level 9, 85 Castlereagh Street, Sydney NSW 2000 | FY2020 AR, Corporate Directory |
| Share registry | Boardroom Pty Limited, Level 12, 225 George Street, Sydney NSW 2000 | FY2020 AR |
| Exchange / ticker | ASX: IQ3 (listed 18 May 2015; suspended; removed 26 Aug 2022) | [2022] FCA 397; ASX Market Announcement 29 Aug 2022 |
| ISIN | Not publicly disclosed in sources retrieved (AU-prefixed ISIN would have applied) | — |
| CUSIP | Not applicable (no US listing) | — |
| Fiscal year end | 30 June | FY2020 AR |
| Employees | Not publicly disclosed. Proxy: employee benefits expense A$1.76m (FY2020) vs A$2.87m (FY2019) | FY2020 AR, Note 7 |
| Auditor (last) | Vincents Audit Pty Ltd, Canberra (engagement director Phillip William Miller CA) | FY2020 AR, auditor's independence declaration |
| Regulatory licence status | Corporate authorised representative of AFSL 451144 | FY2020 AR, Review of operations |
| Shares on issue (30 Jun 2020) | 103,925,001 fully paid ordinary shares | FY2020 AR, Note 20 |
| Market capitalisation (current) | Not applicable (delisted). Last quoted price A$0.12, implying about A$12.5m on 103.9m shares (historical, illiquid) | Investing.com historical data |
| Market capitalisation at IPO | A$30.545m at A$0.30 per share | IPO close announcement, May 2015 |
| Website | http://iq3corp.com (as supplied; www.iQ3Corp.com cited in FY2020 AR). | FY2020 AR |
| External administrators | Mark Robinson, Riad Tayeh and Antony Resnick (joint and several) | [2022] FCA 397 |
iQ3Corp Ltd was a micro-cap Australian corporate finance boutique that described itself as the world's first dedicated life science corporate finance and advisory firm. It provided capital raising, IPO and listing advisory, M&A, structured finance, restructuring and NSX nominated-adviser services to biotech, medtech and pharmaceutical companies in Australia and, through US subsidiaries, the United States. In practice it was a captive service provider inside the "iQ Group" of companies founded by Dr George Syrmalis. Its FY2020 accounts state that 100% of revenue came from related parties, and the group's administrators later described a web of intercompany loans and shared-labour arrangements. Revenue grew from A$2.1m (FY2016) to A$6.9m (FY2020), but losses widened, equity turned negative and the auditor flagged a going-concern material uncertainty. The group collapsed into voluntary administration in March 2022, and iQ3Corp was delisted from the ASX in August 2022. It is now a distressed-asset and governance case study rather than a going concern.
---
### Company's own description (FY2020 Annual Report)
The FY2020 Directors' Report gives the principal activity as the provision of capital raising and corporate advisory services to listed and unlisted companies in the life science industry. The Review of Operations positions the company as a specialist corporate finance adviser to the life science sector. It describes expertise in mergers and acquisitions, strategic matters, restructuring and capital structure, and capital raising, offered to corporations, partnerships, institutions, governments and individuals. The FY2019 Annual Report called iQ3Corp the world's first dedicated life science corporate finance firm, under the tagline "Translating Science into Capital and Beyond".
In FY2020 management said the company had advised boards and executives on the best business model for commercialising new life science intellectual property. That work covered market entry, funding, licensing and partnering strategies, and identifying counterparties in Australia and offshore. Management also cited new projects and collaborations with US business partners, which it expected to produce a pipeline of work over the following 12–24 months.
Aggregator profiles (MarketBeat, Investing.com) add IPO and listing advisory, private equity, structured finance, sell-side and buy-side mandates, and NSX nominated-adviser services to the list.
### Business model and revenue model
| Revenue stream | Model type | FY2020 (A$) | FY2019 (A$) | Share of FY2020 revenue |
|---|---|---|---|---|
| Capital raising and corporate advisory fees | Professional services: project/success fees, fixed price or hourly | 6,760,211 | 5,647,659 | 98.0% |
| Office and shared services revenue | Cost-recovery / service fees charged to related entities | 139,757 | 513,190 | 2.0% |
| Total | — | 6,899,968 | 6,160,849 | 100% |
Source: FY2020 Annual Report, Notes 4 and 5. All revenue was recognised over time as services were rendered, on either a fixed price or an hourly rate (Note 5 accounting policy). There was no product, subscription or licensing revenue. The company did hold "licences" as an indefinite-life intangible asset (A$307,986 at 30 June 2020), but these generated no disclosed revenue.
### Independent characterisation
On paper, iQ3Corp was an advisory boutique. Economically, it functioned as a related-party service vehicle. Three disclosures from FY2020 are decisive:
1. **Customer concentration of 100% to related parties.** Note 4 states that the Group's revenue came only from related parties. Note 30 confirms that all A$6.76m of advisory fees and all A$0.14m of shared-services fees were received from related parties. The related entities were The iQ Group Global Ltd (formerly iQnovate), iQX Limited, OncoTEX entities, Biosensx (North America) Pty Ltd and New Frontier Holdings LLC.
2. **Cash conversion was weak.** Related-party receivables were A$2.48m gross at 30 June 2020, against FY2020 revenue of A$6.90m, or roughly 126 days of revenue.
3. **Funding came from inside the group.** Liquidity relied on a A$927,000 bond from related party iQX (9% coupon, maturing 30 June 2022) and an undrawn A$3m iQX working capital facility, also at 9%. The going-concern basis rested on related-party capital-raising fees and related-party funding.
The auditor's key audit matters were going concern, related party transactions, and recognition and impairment of intangibles. The audit report described a group of subsidiaries and companies with varying ownership levels, which transacted with one another and performed similar functions in different market sectors.
The administrators' evidence to the Federal Court in April 2022 confirmed this picture. Entities in the iQ Group relied on each other for day-to-day funding. There were many intercompany loans, often written off or reclassified without adequate explanation, and loan balances were inconsistent between counterparties. Entities sometimes paid other entities' employees, and shared-labour arrangements were common. The administrators considered Farmaforce, not iQ3Corp, to be the group's principal operating company ([2022] FCA 397, paras 4–5).
### Value chain position
| Value-chain stage | Activity | iQ3Corp role |
|---|---|---|
| Discovery / IP origination | University and research-institute IP, early-stage biotech | None directly; sourced via sister company iQ Group Global (IP asset manager) |
| Corporatisation and structuring | Company formation, IP licensing, structuring | Advisory (stated FY2020 focus: "finding, funding, corporatising and capitalising early stage biotech assets", per Lei Xu biography) |
| Capital raising | Seed, pre-IPO, IPO, secondary raisings | Core fee-earning service |
| Listing / nominated adviser | ASX and NSX listings; NSX nominated adviser | Service offered (NSX nominated adviser per aggregator profiles) |
| Investment / funds management | Bioscience funds | Sister company iQX Limited (NSX: IQX) |
| Commercial execution | Pharma sales forces, medical affairs | Sister company Farmaforce Ltd (ASX: FFC) |
iQ3Corp sat between life science asset originators and capital markets:
### Customer types and end-markets
| Customer type | Evidence | Notes |
|---|---|---|
| Related-party life science companies | FY2020 AR Note 30: 100% of revenue | iQ Group Global, iQX, OncoTEX, Biosensx, New Frontier |
| Listed and unlisted biotech/medtech | Stated target market | No disclosed third-party clients in FY2020 |
| Governments, institutions, individuals | Stated in boilerplate | No disclosed revenue |
| US life science companies | US subsidiaries (iQ Capital (USA) LLC etc.) | Revenue geographically disclosed as Australia only |
End-markets: biotechnology, medical devices and diagnostics (notably saliva-based biosensors developed within the wider iQ Group), oncology (OncoTEX associate) and pharmaceutical services.